Status:
COMPLETED
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)
Lead Sponsor:
Cell Genesys
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer...
Eligibility Criteria
Inclusion
- Diagnosis of adenocarcinoma prostate cancer
- No evidence of measurable metastatic disease
- An ECOG performance status of 0 or 1
Exclusion
- Previous hormonal therapy of any type for prostate cancer
- Any previous chemotherapy, or prior investigational therapy for prostate cancer
- Prior Immunotherapy
- Prior treatment with gene therapy
Key Trial Info
Start Date :
May 1 1999
Trial Type :
INTERVENTIONAL
End Date :
March 1 2001
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00140387
Start Date
May 1 1999
End Date
March 1 2001
Last Update
September 1 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.